Tesamorelin: GHRH Analog Research Guide 2026

<p>Tesamorelin (trade name Egrifta) is a synthetic analog of GHRH consisting of the full 44-amino acid sequence with a trans-3-hexenoic acid conjugate at the N-terminus. It is one of the few research peptides with both an FDA-approved indication (visceral adipose tissue reduction in HIV-associated lipodystrophy) and extensive basic research utility, making it a uniquely well-characterized compound for laboratory investigation.</p><h2>Molecular Profile</h2><p>Sequence: Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 | MW: 5135.9 g/mol | CAS: 218949-48-5</p><h2>GHRH Receptor Mechanism</h2><p>Like endogenous GHRH, tesamorelin activates the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and pulsatile release. The N-terminal trans-3-hexenoic acid modification provides resistance to DPP-IV cleavage, extending half-life relative to native GHRH while maintaining full receptor binding activity. This makes tesamorelin valuable for studying sustained GHRH receptor activation in research models.</p><h2>Visceral Adipose Tissue Research Context</h2><p>The FDA-approved indication for tesamorelin — reduction of excess visceral adipose tissue (VAT) in adults with HIV-associated lipodystrophy — has generated a substantial body of clinical trial data that informs preclinical research model design. Published Phase 3 trial data documented statistically significant reductions in VAT area with corresponding changes in IGF-1 levels, providing quantitative reference parameters for laboratory investigators.</p><p>↗ Falutz J et al. (2010). Effects of tesamorelin on visceral adiposity and liver fat in HIV-infected patients with abdominal fat accumulation. AIDS. PubMed ID: 20400886</p><h2>Research Applications</h2><ul><li>GHRH receptor activation and GH axis studies</li><li>Adipose tissue biology and lipid metabolism pathway research</li><li>IGF-1 axis investigation in preclinical models</li><li>Body composition research models</li></ul><h2>Frequently Asked Questions</h2><p>Q: Is tesamorelin FDA approved?</p><p>A: Yes — tesamorelin is FDA-approved as Egrifta for a specific indication. Research-grade tesamorelin is for in-vitro laboratory research only and is not a pharmaceutical product.</p><p>Q: Why is tesamorelin longer than other GHRH analogs?</p><p>A: Tesamorelin represents the full 44-amino acid GHRH sequence (compared to CJC-1295/sermorelin's 29-amino acid fragment) with the N-terminal modification for stability.</p><p>Related: Tesamorelin Product → | CJC-1295 Research Guide → | Sermorelin Research Guide → | IGF-1 LR3 Research Guide →</p>